Chris Jackson is a Consultant Medical Oncologist with the Southern Blood and Cancer Service (Southern DHB) and Senior Lecturer in Medicine with the University of Otago. He trained in Gastrointestinal Oncology as Clinical Research Fellow in the Gastrointestinal Cancer Unit of the Royal Marsden NHS Foundation Trust, and was later appointed to Locum Consultant at the Trust. He returned to his present post in 2008. He is currently lead for Cancer Trials at the Southern Blood and Cancer Centre, an active investigator in several collaborative clinical studies, Principal Investigator in the Cancer Immunology Therapeutics Research Group at the University of Otago, and Scientific Advisor to Cancer Trials NZ and the Centre for Translational Cancer Research. Chris is currently Chair of the South Island Bowel Cancer Working Group and a member of the National Bowel Cancer Work Group. Current projects include Genetics of Chemotherapy Toxicity, Immunotherapies in Colorectal Cancer, and he is the Clinical Lead for the PIPER colorectal cancer outcomes project.
Supported by:
| Colorectal Cancer - NZ's cancer
Main Session |
|||
| Friday, 13 June 2014 | Start 5:45pm | Duration: 25mins | Baytrust |
| Colorectal Cancer in NZ
Concurrent Workshop Repeated |
|||
| Saturday, 14 June 2014 | Start 2:00pm | Duration: 55mins | Room 5 |
| Start 3:05pm | Duration: 55mins | Room 5 | |
| Colorectal Cancer (CRC) a major health problem in NZ. It is the second most common cancer, and the second leading cause of cancer deaths. Whilst rates are falling, there are increasing numbers of new cases each year due to an aging population. The symptoms are often vague and non-specific, and can be difficult to distinguish from less important illnesses. Maori are more likely to be diagnosed with cancer (in general), and once diagnosed are more likely to die from cancer. This workshop will address the scope of the CRC problem in New Zealand compared to other countries. We will discuss how to identify, reduce or even eliminate such inequities in cancer-related outcomes. We will examine improvements in the detection and treatment of early and advanced cancer. Current policy initiatives, programmes, public health campaigns, and patient-led initiatives will be canvassed to consider what is being done to manage this growing problem. | |||